Protecting Life and Integrity in Research Act of 2025

The Protecting Life and Integrity in Research Act of 2025, HR2075, directly prohibits any Federal department, agency, or office from conducting, funding, approving, or otherwise supporting research involving human fetal tissue obtained from induced abortions. This includes the solicitation or knowing acquisition, receipt, or acceptance of donations of such tissue. The bill explicitly permits research on human fetal tissue obtained after a miscarriage or stillbirth and allows for the development of new, high-efficiency cell lines not derived from induced abortion tissue. This legislative action immediately redefines the scope of federally funded biomedical research, forcing a shift in research methodologies and supply chains for affected projects. The money trail for this legislation involves the reallocation of existing federal research funds. While no new appropriations are specified, federal grants and contracts previously supporting research using induced abortion-derived fetal tissue will now be redirected or terminated. Companies that supply reagents, equipment, and services for such research, including Thermo Fisher Scientific ($TMO) and Danaher Corporation ($DHR), will see a reduction in demand from federally funded projects in this specific area. Conversely, companies developing or utilizing alternative cell lines or those focused on research using tissue from miscarriages or stillbirths may see increased federal support. The National Institutes of Health (NIH) is the primary federal agency funding such research, and its grant-making priorities will shift in accordance with this bill. Historically, similar restrictions on federal funding for human embryonic stem cell research occurred under President George W. Bush's administration in 2001. This led to a slowdown in certain areas of stem cell research within the U.S. and a shift of some research to private funding or international institutions. While not directly comparable in scope, the 2001 restrictions demonstrated that federal funding limitations can significantly alter research trajectories and impact the market for research tools and therapeutic development. When President Obama lifted these restrictions in 2009, companies involved in stem cell research, such as Advanced Cell Technology (now part of Astellas Pharma), saw renewed interest, though direct market impact was difficult to isolate due to broader market conditions. Specific losers include companies whose research or product development relies on federally funded projects utilizing induced abortion-derived fetal tissue. This could indirectly affect early-stage drug discovery for conditions where such tissue was a research model. Companies like Biogen ($BIIB), Gilead Sciences ($GILD), Moderna ($MRNA), and Pfizer ($PFE), which engage in extensive federally funded research, will need to ensure their projects comply, potentially incurring costs for methodology changes. Winners are less clear-cut but could include companies specializing in alternative cell culture technologies or those focused on research using ethically sourced tissue, though no specific publicly traded companies are exclusively positioned for this shift at present. The bill's allowance for "new, ethical cell lines" creates a potential growth area for companies developing such alternatives. This bill has been referred to the House Committee on Energy and Commerce. The next step is committee consideration, including potential hearings and markups. If it passes committee, it will proceed to a full House vote. Given the 33 cosponsors, including several senior members, the bill has significant legislative momentum within the House. If passed by the House, it would then move to the Senate for consideration. The timeline for passage is uncertain but could occur within the current legislative session.